Fulcrum Therapeutics, Inc.
FULCNasdaqSmall CapHealthcare
13F Pro Quality Score
32.9/100
Rank #2,179 of 2,719 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
99.7/100
Profitability
7.8/100
Balance Sheet
8.2/100
Earnings Quality
18.0/100
Free Cash Flow
6.8/100
Institutional Flow
83.1/100
Revenue Scale
14.0/100
Dilution Risk
8.6/100
Price Chart
Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.
Reading the latest SEC filing… (first load can take ~20s)
Key Metrics
Top Institutional Holders
as of Q2 2026$32.30M+63.7%
$23.97MNew
$23.87MNew
$20.04M+79.5%
$13.47M-43.9%
$11.14M+87.5%
$9.90M+7170.2%
$9.87M+0.2%
$8.12MNew
$7.46M+31.4%
Financial Trends
Revenue & Net Income
Earnings Per Share
Loading ratio trend…